Efficacy of VP2 protein expressed in E. coli for protection against highly virulent infectious bursal disease virus.
The ability of a heat-inactivated whole virus from a highly virulent infectious bursal disease virus (hvIBDV) and VP2 protein from hvIBDV expressed in E. coli provided protection against a hvIBDV challenge in specificpathogen-free (SPF) chickens. Six out of seven chickens that were injected three times with crude VP2 protein developed significant antibody titer against IBDV. However, only four out of the seven chickens survived the hvIBDV challenge. Despite showing low antibody titer profiles, all chickens immunized with the heat-inactivated whole virus also survived the challenged with hvIBDV. However, all of these chickens had bursal atrophy and mild to moderate depletion of lymphocytes. Thus, antibodies raised against IBDV VP2 protein expressed in E. coli and denatured IBDV proteins induced some degree of protection against mortality but not against bursal damage following challenge with hvIBDV.
Omar
Abdul Rahman
AR
Institute of Bioscience, University Putra Malaysia, 43400 UPM Serdang, Selangor Darul Ehsan, Malaysia. aro@ibs.upm.edu.my
Kim
Chong Lee
CL
Bejo
Mohd Hair
MH
Ideris
Aini
A
D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D018175:Birnaviridae Infections / Q000276:immunology / Q000517:prevention & control / Q000662:veterinary* / Q000821:virology; D002645:Chickens; D004797:Enzyme-Linked Immunosorbent Assay / Q000662:veterinary; D004926:Escherichia coli / Q000235:genetics; D007114:Immunization / Q000592:standards / Q000662:veterinary*; D007243:Infectious bursal disease virus / Q000235:genetics / Q000276:immunology* / Q000472:pathogenicity; D011201:Poultry Diseases / Q000276:immunology* / Q000517:prevention & control / Q000821:virology; D011994:Recombinant Proteins / Q000235:genetics / Q000276:immunology*; D013047:Specific Pathogen-Free Organisms; D014613:Vaccines, Attenuated / Q000276:immunology / Q000494:pharmacology; D014614:Vaccines, Synthetic / Q000276:immunology / Q000494:pharmacology; D015678:Viral Structural Proteins / Q000096:biosynthesis / Q000235:genetics / Q000276:immunology*; D014765:Viral Vaccines / Q000276:immunology* / Q000494:pharmacology
D000914:Antibodies, Viral; D011994:Recombinant Proteins; C082513:VP2 protein, infectious bursal disease virus; D014613:Vaccines, Attenuated; D014614:Vaccines, Synthetic; D015678:Viral Structural Proteins; D014765:Viral Vaccines